Keyword: benralizumab

AstraZeneca’s hopes for expanding severe asthma drug Fasenra into COPD are officially lost.

AZ was hoping its next-gen COPD med Fasenra could help it keep pace with GlaxoSmithKline, but the drug just failed to beat placebo in a phase 3 study.

Teva was hoping to level the convenience playing field in severe asthma with a subcutaneous version of Cinqair. But those plans have hit a snag.

GlaxoSmithKline may have some new Nucala competition in severe asthma, but it also has a new market all to itself.

GSK just inherited its biggest threat to Nucala in the form of a new AZ rival. But the British drugmaker says it’s down for some marketplace battling.

AstraZeneca is about to find out whether its third-to-market respiratory biologic can stand out from a crowd that includes rivals GSK and Teva.

With approval pending for benralizumab, AstraZeneca is preparing to move into the respiratory biologics space—and it’s not taking the task lightly.

AstraZeneca wants asthma patients to know their treatment plans should be as unique and specific as their fingerprints. Its solution? Lungprint.

Amid plenty of CEO speculation, Teva got some good news Thursday on the respiratory front.

GSK’s Nucala may soon get more competition in the severe asthma market. So the company is setting out to test Nucala in other populations, too.